Cutting edge: Permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection

Journal of Immunology

Volumn 182, Issue 3, 2009, Pages 1242-1246

  Klyushnenkova, Elena N ^a,b   Kouiavskaia, Diana V ^a   Berard, Carla A ^c   Alexander, Richard B ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DR ANTIGEN; HLA DR2B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER ANTIBODY; CD8 ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR2 ANTIGEN; HLA DRB1*1501, HUMAN; HLA-DRB1*1501, HUMAN; I A(B) ANTIGEN, MOUSE; I-A(B) ANTIGEN, MOUSE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE; TUMOR REJECTION; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; INCIDENCE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ALLELES; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HLA-DR2 ANTIGEN; HUMANS; INCIDENCE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 63149091820     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.3.1242     Document Type: Article

References (17)

1. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
2. + T lymphocytes: Critical components of antitumor immunity. Cancer Invest. 23: 413-419.
3. Cunha, A. C., B. Weigle, A. Kiessling, M. Bachmann, and E. P. Rieber. 2006. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 236: 229-238.
4. Lilja, H., D. Ulmert, and A. J. Vickers. 2008. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer. 8: 268-278.
5. Klyushnenkova, E. N., S. Ponniah, A. Rodriguez, J. Kodak, D. L. Mann, A. Langerman, M. I. Nishimura, and R. B. Alexander. 2004. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J. Immunother. 27: 136-146.
6. Klyushnenkova, E. N., J. Link, W. T. Oberle, J. Kodak, C. Rich, A. A. Vandenbark, and R. B. Alexander. 2005. Identification of HLA-DRB1*1501- restricted T-cell epitopes from prostate-specific antigen. Clin. Cancer Res. 11: 2853-2861.
7. Foster, B. A., J. R. Gingrich, E. D. Kwon, C. Madias, and N. M. Greenberg. 1997. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57: 3325-3330.
8. Medin, J. A., S. B. Liang, J. W. Hou, L. S. Kelley, D. J. Peace, and D. H. Fowler. 2005. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 12: 540-551.
9. Grossmann, M. E., M. Wood, and E. Celis. 2001. Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines. World J. Urol. 19: 365-370.
10. Madsen, L. S., E. C. Andersson, L. Jansson, M. Krogsgaard, C. B. Andersen, J. Engberg, J. L. Strominger, A. Svejgaard, J. P. Hjorth, R. Holmdahl, et al. 1999. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23: 343-347.
11. Pavlenko, M., C. Leder, A. K. Roos, V. Levitsky, and P. Pisa. 2005. Identification of an immunodominant H-2D(b) -restricted CTL epitope of human PSA. Prostate 64: 50-59.
12. van Hall, T., N. E. van de Rhee, S. P. Schoenberger, M. P. Vierboom, F. A. Verreck, C. J. Melief, and R. Offringa. 1998. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res. 58: 3087-3093.
13. Nelson, W. G., A. M. De Marzo, and W. B. Isaacs. 2003. Prostate cancer. N. Engl. J. Med. 349: 366-381.
14. Taylor, B. S., M. Pal, J. Yu, B. Laxman, S. Kalyana-Sundaram, R. Zhao, A. Menon, J. T. Wei, A. I. Nesvizhskii, D. Ghosh, et al. 2008. Humoral response profiling reveals pathways to prostate cancer progression. Mol. Cell. Proteomics 7: 600-611.
15. Tan, T. T., and L. M. Coussens. 2007. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 19: 209-216.
16. McNeel, D. G., L. D. Nguyen, B. E. Storer, R. Vessella, P. H. Lange, and M. L. Disis. 2000. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J. Urol. 164: 1825-1829.
17. Fossa, A., A. Berner, S. D. Fossa, E. Hernes, G. Gaudernack, and E. B. Smeland. 2004. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59: 440-447.